c-MET (D1228H)

MET · Variant type: point · HGVS: p.D1228H

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Gilteritinib	92.8%	7.3%	88.97
2	Cabozantinib	85.9%	14.1%	92.73
3	Tivozanib	82.9%	17.1%	92.42
4	Pacritinib	76.5%	23.5%	88.64
5	Crizotinib	75.0%	24.9%	91.39
6	Defactinib	71.9%	28.1%	92.68
7	Neratinib	66.0%	34.0%	93.18
8	Repotrectinib	63.1%	36.9%	84.21
9	Selpercatinib	60.5%	39.5%	96.72
10	Fostamatinib	58.4%	41.6%	96.74
11	Imatinib	47.8%	52.2%	99.00
12	Osimertinib	47.5%	52.5%	97.24
13	Tepotinib	36.8%	63.2%	99.75
14	Canertinib	36.6%	63.4%	96.49
15	Capmatinib	33.3%	66.7%	99.75
16	Fedratinib	33.3%	66.7%	96.21
17	Sunitinib	29.6%	70.4%	91.73
18	Lenvatinib	28.0%	72.0%	97.74
19	Abemaciclib	27.5%	72.5%	91.48
20	Trametinib	23.9%	76.1%	99.50
21	Ibrutinib	23.8%	76.2%	94.74
22	Brigatinib	23.5%	76.5%	82.96
23	Ribociclib	22.0%	78.0%	99.25
24	Vemurafenib	20.1%	79.9%	96.49
25	Entrectinib	19.3%	80.7%	93.69

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Gilteritinib	92.8%	—	—
Cabozantinib	85.9%	—	—
Tivozanib	82.9%	—	—
Pacritinib	76.5%	—	—
Crizotinib	75.0%	—	—
Defactinib	71.9%	—	—
Neratinib	66.0%	—	—
Repotrectinib	63.1%	—	—
Selpercatinib	60.5%	—	—
Fostamatinib	58.4%	—	—
Imatinib	47.8%	—	—
Osimertinib	47.5%	—	—
Tepotinib	36.8%	—	—
Canertinib	36.6%	—	—
Capmatinib	33.3%	—	—
Fedratinib	33.3%	—	—
Sunitinib	29.6%	—	—
Lenvatinib	28.0%	—	—
Abemaciclib	27.5%	—	—
Trametinib	23.9%	—	—
Ibrutinib	23.8%	—	—
Brigatinib	23.5%	—	—
Ribociclib	22.0%	—	—
Vemurafenib	20.1%	—	—
Entrectinib	19.3%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 64.9ms